Inclisiran (Leqvio) Mechanism of Action: The Full Pathway Explained

Why PCSK9 Matters for LDL Clearance

The liver removes roughly 70% of circulating LDL cholesterol through LDL receptors (LDLR) on hepatocyte surfaces. PCSK9, a serine protease produced primarily by hepatocytes, binds to these receptors and routes them toward lysosomal degradation instead of recycling. The result is fewer receptors available to pull LDL particles out of the blood.

PCSK9 and LDL Receptor Recycling

Under normal physiology, an LDL receptor binds an LDL particle, the complex is internalized via clathrin-coated pits, and the receptor releases its cargo in the acidic endosome before returning to the cell surface. Each receptor can cycle through this process approximately 150 times over a 20-hour lifespan 1. When PCSK9 binds the receptor's epidermal growth factor-like repeat A (EGF-A) domain at the cell surface, the receptor is diverted to the lysosome and destroyed.

Gain-of-Function and Loss-of-Function Genetics

Gain-of-function mutations in PCSK9 cause familial hypercholesterolemia with LDL-C levels exceeding 190 mg/dL. Loss-of-function variants do the opposite. The Dallas Heart Study found that carriers of the PCSK9 nonsense mutation C679X had a 28% reduction in mean LDL-C and an 88% lower incidence of coronary heart disease over 15 years of follow-up 2. That genetic proof-of-concept made PCSK9 one of the most validated drug targets in cardiovascular medicine.

From Antibodies to RNA Interference

Monoclonal antibodies (evolocumab, alirocumab) were the first class to exploit this target. They intercept PCSK9 protein in the circulation. Inclisiran takes a different approach entirely: it prevents the protein from being made in the first place, silencing the gene's mRNA transcript inside the hepatocyte.

The siRNA Architecture of Inclisiran

Inclisiran is a double-stranded, chemically modified siRNA. Its sense strand is 21 nucleotides long; the antisense (guide) strand is 23 nucleotides. Both strands carry 2'-O-methyl and 2'-fluoro modifications at specific positions, and several internucleotide linkages are replaced with phosphorothioate bonds 3.

Chemical Modifications That Prevent Degradation

Unmodified siRNA survives only minutes in plasma before nucleases destroy it. The 2'-O-methyl groups protect the ribose sugar from endonuclease attack. Phosphorothioate linkages at the 3' and 5' termini resist exonuclease digestion. The 2'-fluoro substitutions improve duplex thermostability without adding bulk. Together, these changes extend the molecule's half-life and keep it intact during transit from the injection site to the liver 3.

The GalNAc Conjugate: Precision Liver Targeting

Covalently linked to the 3' end of the sense strand is a triantennary GalNAc ligand. This sugar cluster binds with high affinity to asialoglycoprotein receptors (ASGPR), which are expressed at a density of approximately 500,000 copies per hepatocyte and are nearly absent from other cell types 4. The ASGPR undergoes constitutive endocytosis, recycling every 10 to 15 minutes. Once the GalNAc-siRNA conjugate binds, it is rapidly internalized.

This targeting strategy achieves two things at once. It concentrates the drug in hepatocytes (the cells that produce PCSK9), and it avoids systemic siRNA exposure that could trigger off-target gene silencing or immune activation in other tissues.

From Endosome to RISC: The Intracellular Silencing Pathway

After receptor-mediated endocytosis delivers inclisiran into the hepatocyte endosome, the drug must escape into the cytoplasm to reach the RNA-induced silencing complex (RISC). This endosomal escape step is the rate-limiting event for all siRNA therapeutics. Only a small fraction of internalized molecules (estimated at 1% to 2%) reaches the cytoplasm, but because ASGPR recycles so rapidly, the hepatocyte continually re-internalizes any conjugate that failed to escape on the first pass 4.

RISC Loading and Strand Selection

Once in the cytoplasm, the siRNA duplex is loaded onto Argonaute 2 (AGO2), the catalytic engine of RISC. AGO2 unwinds the duplex and retains the antisense (guide) strand while discarding the sense strand. The retained guide strand programs AGO2 to recognize a complementary 21-nucleotide sequence within the PCSK9 mRNA transcript 5.

mRNA Cleavage and Catalytic Turnover

When the programmed RISC encounters PCSK9 mRNA, AGO2 cleaves the transcript between nucleotide positions 10 and 11 of the guide strand's binding site. The cleaved mRNA fragments are released and degraded by cellular exonucleases. The guide strand remains loaded on AGO2 and is free to bind and destroy another copy of PCSK9 mRNA. This catalytic turnover is what gives siRNA therapeutics their prolonged duration of effect. A single loaded RISC complex can silence hundreds to thousands of mRNA copies before the guide strand is eventually degraded 5.

Why the Effect Lasts Six Months

The durability of inclisiran comes from three compounding factors. First, GalNAc-siRNA conjugates accumulate in a hepatocyte depot that slowly feeds active drug into the cytoplasm over weeks. Second, AGO2-loaded guide strands are remarkably stable, with intracellular half-lives measured in weeks rather than hours. Third, hepatocyte turnover in a healthy adult liver is slow (hepatocyte half-life is approximately 200 to 300 days), so cells carrying active RISC persist for months 6. The net result is sustained PCSK9 suppression from a single 284 mg subcutaneous injection, with the clinical effect beginning to wane only around month five or six.

Downstream Effect: LDL Receptor Upregulation

With PCSK9 mRNA silenced, the hepatocyte produces far less PCSK9 protein. The ORION-1 dose-finding study measured circulating PCSK9 levels and found that inclisiran 300 mg reduced free PCSK9 by up to 83.8% at day 60, with suppression persisting through day 180 7.

More Receptors, More LDL Clearance

Without PCSK9-mediated degradation, LDL receptors accumulate on the hepatocyte surface. Each receptor that survives destruction can complete its full 150-cycle lifespan. The amplified receptor density increases the rate at which circulating LDL particles are captured and internalized. The clinical translation: LDL-C drops.

How This Compares to Statin-Induced LDLR Upregulation

Statins upregulate LDL receptor expression by inhibiting HMG-CoA reductase, which depletes intracellular cholesterol and triggers SREBP-2-mediated transcription of the LDLR gene. But statins also upregulate PCSK9 transcription through the same SREBP-2 pathway 8. This counter-regulatory effect partially blunts the LDL-lowering benefit. Inclisiran, by silencing PCSK9 mRNA, removes that brake. The combination of a statin plus inclisiran produces complementary LDL receptor upregulation through two distinct molecular levers: more receptors made (statin) and more receptors preserved (inclisiran).

Clinical Proof: ORION-10 and ORION-11

The phase III ORION-10 (N=1,561; United States) and ORION-11 (N=1,617; Europe and South Africa) trials enrolled patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents already receiving maximally tolerated statin therapy 9.

Primary Efficacy Results

At day 510 (approximately 17 months), inclisiran reduced LDL-C by 52.3% in ORION-10 and 49.9% in ORION-11 compared with placebo (P<0.001 for both) 9. The time-averaged LDL-C reduction across the dosing interval was 53.8% and 49.2%, respectively. These reductions were achieved on top of baseline statin therapy.

Dr. Kausik Ray, lead investigator for ORION-11 and Professor of Public Health at Imperial College London, stated: "The twice-yearly dosing schedule addresses one of the biggest challenges in cardiovascular prevention, which is long-term adherence to lipid-lowering therapy" 9.

Safety Profile

Injection-site reactions occurred in 5% of inclisiran-treated patients versus 0.7% on placebo. These were mild, transient, and did not lead to treatment discontinuation in either trial. Rates of serious adverse events, hepatic events, and renal events were similar between inclisiran and placebo groups 9. No anti-drug antibodies were detected. The 2020 Endocrine Society scientific statement on lipid management noted: "RNA interference-based therapies represent a mechanistically distinct approach to PCSK9 inhibition that may improve treatment persistence through infrequent dosing" 10.

Long-Term Data From ORION-3 and ORION-8

The open-label extension study ORION-3 followed patients for up to four years, demonstrating that LDL-C reductions of approximately 45% to 50% were maintained with continued twice-yearly dosing and no new safety signals emerged 11. ORION-8 pooled long-term follow-up from multiple ORION trials and confirmed consistent efficacy through year three with no evidence of hepatotoxicity or immune-mediated adverse events 11.

Inclisiran Versus PCSK9 Monoclonal Antibodies

Both drug classes target PCSK9 and produce similar LDL-C reductions (approximately 50% to 60%). The differences are mechanistic, pharmacokinetic, and practical.

Where They Act

Evolocumab and alirocumab are monoclonal antibodies that bind circulating PCSK9 protein in the bloodstream. They must be present continuously to neutralize newly secreted PCSK9. Inclisiran works upstream, inside the hepatocyte, preventing PCSK9 synthesis at the mRNA level 3.

Dosing Frequency

Monoclonal antibodies require injections every two to four weeks. Inclisiran requires three injections in the first year (day 0, day 90, then at month 6) and just two per year thereafter. A patient on inclisiran receives 4 to 6 injections per year in year one, dropping to 2 per year, compared with 12 to 26 for antibody-based therapies. That reduction in injection burden is clinically meaningful for adherence.

Cold Chain and Administration Setting

PCSK9 monoclonal antibodies are typically self-administered at home using pre-filled autoinjectors and require refrigerated storage. Inclisiran is administered by a healthcare professional in a clinical setting, which means the injection aligns with routine office visits. The FDA label specifies that Leqvio be administered by a healthcare provider 12.

Pharmacokinetics: Absorption, Distribution, Metabolism

After subcutaneous injection, inclisiran reaches peak plasma concentration in approximately 4 hours. Plasma half-life is short (approximately 9 hours) because the drug is rapidly taken up by hepatocytes via ASGPR binding 12. The molecule is not meaningfully metabolized by cytochrome P450 enzymes, so drug-drug interactions through CYP pathways are not expected.

Renal and Hepatic Considerations

Population pharmacokinetic analyses from the ORION program found no clinically meaningful differences in inclisiran exposure among patients with mild, moderate, or severe renal impairment (eGFR 15 to 89 mL/min/1.73 m²) 12. No dose adjustment is required. Data in patients with severe hepatic impairment (Child-Pugh C) are limited, and the FDA label recommends caution in this population because ASGPR expression may be reduced in advanced liver disease, potentially altering drug uptake.

Practical Dosing and Monitoring

The approved regimen is 284 mg subcutaneously at day 0, day 90 (the loading phase), and then every 6 months. Clinicians should check a fasting lipid panel before initiation and at 90 days following the first maintenance dose.

What to Expect at Each Time Point

Most patients see a measurable LDL-C reduction within 30 days of the first injection. The nadir typically occurs between days 60 and 90. By the day-90 injection, LDL-C has usually fallen 40% to 50% from baseline. The second injection extends and stabilizes this reduction through month 6 and beyond 9.

Missed Dose Guidance

If a maintenance dose is missed by fewer than three months, it should be administered as soon as possible. If more than three months have elapsed, the loading regimen (day 0, day 90) should be restarted per the prescribing information 12.

Clinicians should obtain a repeat lipid panel 90 days after the first maintenance injection to confirm the patient has achieved an adequate LDL-C response before locking in the twice-yearly schedule.